Fig 1: BHPI plus paclitaxel eliminates orthotopic multidrug resistant OVCAR-3 tumorsA. Average tumor weight from each treatment group (n = 5). For the paclitaxel group the secondary growths were included in tumor weight. B. Circulating serum CA125 biomarker quantitation showing the progression of tumors in each treatment group (n = 5). Threshold in humans (dashed line) denotes 35 U/ml of circulating CA125. Data is the mean ± SEM. ***P < 0.001.
Supplier Page from Abnova Corporation for CA125 (Human) ELISA Kit